International Journal of Biological Markers最新文献

{"title":"A functional polymorphism within the distal promoter of <i>RUNX3</i> confers risk of colorectal cancer.","authors":"Huiping Wang,&nbsp;Jin Wang,&nbsp;Danhua Li,&nbsp;Zhansheng Zhu,&nbsp;Dongsheng Pei","doi":"10.1177/17246008211073342","DOIUrl":"https://doi.org/10.1177/17246008211073342","url":null,"abstract":"<p><strong>Background: </strong>Accumulating evidence has indicated that runt-related transcription factor 3 (<i>RUNX3</i>) gene polymorphism (rs7528484) is associated with an alimentary system cancer risk. However, the role of rs7528484 in colorectal cancer is still unclear. The present study aimed to explore the association between rs7528484 and colorectal cancer susceptibility in a Chinese Han population.</p><p><strong>Material and methods: </strong>We firstly investigated the effect of the polymorphism rs7528484 in distal promoter of <i>RUNX3</i> polymorphism on colorectal cancer risk in a Chinese Han population comprising 427 colorectal cancer patients and 503 controls. We then carried out a phenotype-genotype association analysis to validate its influence on the adjacent gene <i>RUNX3</i>.</p><p><strong>Results: </strong>Logistic regression analysis demonstrated that the T allele of rs7528484 was significantly associated with an increased risk for colorectal cancer occurrence in our case-control study (odds ratio = 1.33; 95% confidence interval = 1.09-1.65; <i>P</i> = 0.005). In stratified analysis, the susceptibility of colorectal cancer in the T allele carriers increased among the smokers, III and IV tumor stage, and at the rectum. Furthermore, the T allele was significantly correlated with lower expression of <i>RUNX3</i> in vitro.</p><p><strong>Conclusion: </strong>In summary, the current case-control and genotype-phenotype study provides convincing evidence that functional <i>RUNX3</i> polymorphism (rs7528484) is related to colorectal cancer risk and is a plausible marker for the prediction of colorectal cancer.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"40-46"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39855589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"System analysis of <i>VEGFA</i> in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets.","authors":"Yongli Situ,&nbsp;Qinying Xu,&nbsp;Li Deng,&nbsp;Yan Zhu,&nbsp;Ruxiu Gao,&nbsp;Lei Lei,&nbsp;Zheng Shao","doi":"10.1177/17246008211063501","DOIUrl":"https://doi.org/10.1177/17246008211063501","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;VEGFA is one of the most important regulators of angiogenesis and plays a crucial role in cancer angiogenesis and progression. Recent studies have highlighted a relationship between &lt;i&gt;VEGFA&lt;/i&gt; expression and renal cell carcinoma occurrence. However, the expression level, gene regulation network, prognostic value, and target prediction of &lt;i&gt;VEGFA&lt;/i&gt; in renal cell carcinoma remain unclear. Therefore, system analysis of the expression, gene regulation network, prognostic value, and target prediction of &lt;i&gt;VEGFA&lt;/i&gt; in patients with renal cell carcinoma is of great theoretical significance as there is a clinical demand for the discovery of new renal cell carcinoma treatment targets and strategies to further improve renal cell carcinoma treatment efficacy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study used multiple free online databases, including cBioPortal, TRRUST, GeneMANIA, GEPIA, Metascape, UALCAN, LinkedOmics, Metascape, and TIMER for the abovementioned analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;&lt;i&gt;VEGFA&lt;/i&gt; was upregulated in patients with kidney renal clear cell carcinoma (KIRC) and kidney chromophobe (KICH), and downregulated in patients with kidney renal papillary cell carcinoma (KIRP). Moreover, genetic alterations of &lt;i&gt;VEGFA&lt;/i&gt; were found in patients with renal cell carcinoma as follows: 4% (KIRC), 8% (KICH), and 4% (KIRP). The promoter methylation of &lt;i&gt;VEGFA&lt;/i&gt; was lower and higher in patients with clinical stages of KIRC and stage 1 KIRP, respectively. &lt;i&gt;VEGFA&lt;/i&gt; expression significantly correlated with KIRC and KIRP pathological stages. Furthermore, patients with KICH and KIRP having low &lt;i&gt;VEGFA&lt;/i&gt; expression levels had a longer survival than those having high &lt;i&gt;VEGFA&lt;/i&gt; expression levels. &lt;i&gt;VEGFA&lt;/i&gt; and its neighboring genes functioned in the regulation of protein methylation and glycosylation, as well as muscle fiber growth and differentiation in patients with renal cell carcinoma. Gene Ontology enrichment analysis revealed that the functions of &lt;i&gt;VEGFA&lt;/i&gt; and its neighboring genes in patients with renal cell carcinoma are mainly related to cell adhesion molecule binding, catalytic activity, acting on RNA, ATPase activity, actin filament binding, protease binding, transcription coactivator activity, cysteine-type peptidase activity, and calmodulin binding. Transcription factor targets of &lt;i&gt;VEGFA&lt;/i&gt; and its neighboring genes in patients with renal cell carcinoma were found: HIF1A, TFAP2A, and ESR1 in KIRC; STAT3, NFKB1, and HIPK2 in KICH; and FOXO3, TFAP2A, and ETS1 in KIRP. We further explored the &lt;i&gt;VEGFA&lt;/i&gt;-associated kinase (ATM in KICH as well as CDK1 and AURKB in KIRP) and &lt;i&gt;VEGFA&lt;/i&gt;-associated microRNA (miRNA) targets (MIR-21 in KICH as well as MIR-213, MIR-383, and MIR-492 in KIRP). Furthermore, the following genes had the strongest correlation with &lt;i&gt;VEGFA&lt;/i&gt; expression in patients with renal cell carcinoma: &lt;i&gt;NOTCH4&lt;/i&gt;, &lt;i&gt;GPR4&lt;/i&gt;, and &lt;i&gt;TRIB2&lt;/i&gt; in KIRC; &lt;i&gt;CKMT2&lt;/i&gt;,","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"90-101"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39573907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of the diagnostic performance of serum carbohydrate antigen 19-9 for the detection of gallbladder cancer.","authors":"Xiaolei Zhou","doi":"10.1177/17246008211068866","DOIUrl":"https://doi.org/10.1177/17246008211068866","url":null,"abstract":"<p><strong>Introduction: </strong>Carbohydrate antigen 19-9 (CA19-9) is a well-studied tumor marker, yet its diagnostic value for gallbladder cancer remains unclear. The present meta-analysis was conducted to validate the role of serum CA19-9 for the detection of gallbladder cancer.</p><p><strong>Methods: </strong>A systematic search of digital databases was conducted, complemented by additional hand-searching. Studies that reported serum CA19-9 for the differentiation of gallbladder cancer cases from non-gallbladder cancer controls were considered eligible.</p><p><strong>Results: </strong>A total of 27 studies involving 4300 subjects were included. The pooled sensitivity, specificity, and area under the curve in diagnosing gallbladder cancer were 0.70 (95% confidence interval (CI): 0.63-0.76), 0.92 (95% CI: 0.88-0.94), and 0.89 (95% CI: 0.86-0.92), respectively. The pooled positive likelihood rate, negative likelihood rate, and diagnostic odds rate were 8.30 (95% CI: 5.84-11.69), 0.33 (95% CI: 0.27-0.41), and 25.13 (95% CI: 5.83-39.89), respectively. Meta-regression analysis revealed that there was significantly lower sensitivity (0.69, 95% CI: 0.61-0.77) and specificity (0.91, 95% CI: 0.87-0.95) when CA19-9 was used for the differentiation of gallbladder cancer cases from benign biliary diseases. A better specificity of 0.93 (95% CI: 0.90-0.96) was reached in the setting of a sample size ≥100.</p><p><strong>Conclusions: </strong>Serum CA19-9 can be a potential candidate marker for the detection of gallbladder cancer, which maintains moderate sensitivity and good specificity. Attention should be paid to the control type and sample size, which may affect its diagnostic accuracy. Also, results should be interpreted with caution due to significant heterogeneity primarily caused by different thresholds between included studies.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"81-89"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39660368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer.","authors":"Jia Chen,&nbsp;Dongting Yao,&nbsp;Weiqin Chen,&nbsp;Zhen Li,&nbsp;Yuanyuan Guo,&nbsp;Fan Zhu,&nbsp;Xiaobo Hu","doi":"10.1177/17246008211070018","DOIUrl":"https://doi.org/10.1177/17246008211070018","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to explore the diagnostic efficiency of serum exosomal miR-451a as a novel biomarker for pancreatic cancer.</p><p><strong>Methods: </strong>Serum samples were collected prior to treatment. First, we analyzed microRNA (miRNA) profiles in serum exosomes from eight pancreatic cancer patients and eight healthy volunteers. We then validated the usefulness of the selected exosomal miRNAs as biomarkers in another 191 pancreatic cancer patients, 95 pancreatic benign disease (PB) patients, and 90 healthy controls.</p><p><strong>Results: </strong>The expression of miR-451a in serum-derived exosomes from pancreatic cancer patients was significantly upregulated compared with those from PB patients and healthy individuals. Serum exosomal miR-451a showed excellent diagnostic power in identifying pancreatic cancer patients. In addition, exosomal miR-451a showed a significant association with clinical stage and distant metastasis in pancreatic cancer, and the expression level of serum exosomal miR-451a was sensitive to therapy and relapse.</p><p><strong>Conclusions: </strong>Serum exosomal miR-451a might serve as a novel diagnostic marker for pancreatic cancer.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"74-80"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39888446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypermethylation of the <i>RASSF1A</i> gene promoter as the tumor DNA marker for nasopharyngeal carcinoma.","authors":"Thuan Duc Lao,&nbsp;Hue Hong Thieu,&nbsp;Dung Huu Nguyen,&nbsp;Thuy Ai Huyen Le","doi":"10.1177/17246008211065472","DOIUrl":"https://doi.org/10.1177/17246008211065472","url":null,"abstract":"<p><strong>Background: </strong><i>RASSF1A</i> is a tumor suppressor gene. The methylation of <i>RASSF1A</i> has been reported to be associated with nasopharyngeal tumorigenesis. However, the heterogeneity was high among different studies. A meta-analysis was performed to evaluate the value of <i>RASSF1A</i> methylation for the diagnosis and early screening of nasopharyngeal carcinoma.</p><p><strong>Methods: </strong>Relevant articles were identified by searching the MEDLINE database. Frequency and odds ratio (OR) were applied to estimate the effect of <i>CDH-1</i> methylation based on random-/fixed-effect models. The meta-analysis was performed by using MedCalc^® software. Subgroup analyses were performed by test method, ethnicity, and source of nasopharyngeal carcinoma samples to determine likely sources of heterogeneity.</p><p><strong>Results: </strong>A total of 17 studies, including 1688 samples (1165 nasopharyngeal carcinoma samples, and 523 from non-cancerous samples) were used for the meta-analysis. The overall frequencies of <i>RASSF1A</i> methylation were 59.68% and 2.65% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among the studies included. The association between <i>RASSF1A</i> gene methylation and the risk of nasopharyngeal carcinoma was also confirmed by calculating the OR value of 30.32 (95%CI  = 18.22-50.47) in the fixed-effect model (Q = 16.41, p = 0.36,I² = 8.62, 95% CI = 0.00-45.27). Additionally, the significant association was also found between the methylation of the <i>RASSF1A</i> gene and the subgroups.</p><p><strong>Conclusions: </strong>This is the first meta-analysis that has provided scientific evidence that the methylation of <i>RASSF1A</i> is the potential diagnosis, prognosis, and early screening biomarker for nasopharyngeal carcinoma.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"31-39"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39859305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential diagnostic and prognostic value of the long non-coding RNA SNHG3 in human cancers: A systematic review and meta-analysis.","authors":"Dingting Wang,&nbsp;Longfei Zou,&nbsp;Jian Luo,&nbsp;Conghong Zhang,&nbsp;Huajun Feng,&nbsp;Gang Qin","doi":"10.1177/03936155221077121","DOIUrl":"https://doi.org/10.1177/03936155221077121","url":null,"abstract":"<p><p>Small nucleolar RNA host gene 3 (SNHG3), as a novel long non-coding RNA (lncRNA) participates in the oncogenic processes of various cancers. We combined a systematic review and a meta-analysis to assess the potential role of SNHG3 as a pan-cancer marker for cancer diagnosis and prognosis. Our study comprehensively searched for SNHG3 expression profiling studies from PubMed, Web of Science, Excerpta Medica Database (EMBASE), Cochrane Library, Google Scholar, and The Cancer Genome Atlas (TCGA). The diagnostic capacity of SNHG3 for all cancers in TCGA database was evaluated from the perspective of pooled sensitivity, specificity, diagnostic odds ratio (DOR), area under the curve (AUC) of the summary receiver operating characteristic (sROC) curve. Also, this research studied the correlation of SNHG3 expression and the overall survival to access its prognostic value. A sum total of 11,888 cancer patients and 730 controls from 44 eligible studies were enrolled in this integrated analysis. In TCGA database, SNHG3 was significantly upregulated in most types of cancers (16/33, 48%). The pooled sensitivity, specificity, and DOR with 95% CIs was 0.72 (95% CI: 0.60-0.82), 0.87 (95% CI: 0.84-0.90), and 18 (95% CI: 11-30), respectively. Similarly, the AUC of the sROC curve was 0.89 (95% CI: 0.86-0.92), indicating SNHG3 was highly conserved as a diagnosis biomarker. Additionally, SNHG3 overexpression significantly deteriorated the overall survival of cancer patients (pooled HR = 1.28, 95% CI:1.11-1.48; <i>P</i> < 0.05). These findings suggest that the lncRNA SNHG3 could serve as a promising diagnostic and prognostic biomarker.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"3-12"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39896687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of pretreatment serum superoxide dismutase activity in patients with locoregionally advanced nasopharyngeal carcinoma.","authors":"Wenze Qiu,&nbsp;Jiali Jiang,&nbsp;Zejiang Zhan,&nbsp;Laiji Huang,&nbsp;Jin Deng,&nbsp;Jiacai Ye,&nbsp;Guo Li,&nbsp;Kai Liao,&nbsp;Huanhuan Zhang,&nbsp;Yan Ding,&nbsp;Yawei Yuan,&nbsp;Ronghui Zheng","doi":"10.1177/17246008221075042","DOIUrl":"https://doi.org/10.1177/17246008221075042","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the prognostic effect of pretreatment serum superoxide dismutase (SOD) activity in locoregionally advanced nasopharyngeal carcinoma.</p><p><strong>Methods: </strong>A total of 498 patients diagnosed with stage III-IVA nasopharyngeal carcinoma between January 2013 and December 2016 were involved in this study. The X-tile program was used to determine the cut-off value of pretreatment serum SOD activity based on disease-free survival. Kaplan-Meier methods and Cox proportional hazards models were used to evaluate the impact of serum SOD levels on survival outcomes. The receiver operating characteristic (ROC) curve analysis was used to compare the prognostic value of clinical stage, pretreatment serum SOD level, and the combination of them regarding disease-free survival.</p><p><strong>Results: </strong>Based on the X-tile plot, the optimal cutoff value of pretreatment serum SOD activity for disease-free survival was 146.0U/mL. As a dichotomous variable, SOD was significantly higher in non-keratinizing differentiated disease (<i>P</i> = 0.027) and early T stage (<i>P</i> = 0.011). Compared with the lower subset, higher SOD activity predicted an inferior 3-year rates of overall survival (84.6 vs. 94.7%, <i>P</i> < 0.001), distant metastasis-free survival (78.3 vs. 92.8%, <i>P</i> < 0.001) and disease-free survival (78.2 vs. 92.8%, <i>P</i> < 0.001). Multivariate analysis verified that the SOD activity was an independent prognostic indicator to predict distant metastasis, disease progression, and death. The area under the ROC curve (AUC) of the combination was superior to that of clinical stage or SOD alone for disease-free survival (both <i>P</i> < 0.01).</p><p><strong>Conclusion: </strong>Serological SOD activity before treatment is an important prognostic indicator for patients with stage III-IV non-metastatic nasopharyngeal carcinoma undergoing chemoradiation therapy.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"21-30"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39751429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the association with disease recurrence of miRNAs predictive of colorectal cancer.","authors":"Susanna Zanutto,&nbsp;Chiara Maura Ciniselli,&nbsp;Antonino Belfiore,&nbsp;Valentina Dall'Olio,&nbsp;Laura Tizzoni,&nbsp;Luca Varinelli,&nbsp;Marco Alessandro Pierotti,&nbsp;Luigi Battaglia,&nbsp;Paolo Verderio,&nbsp;Marcello Guaglio,&nbsp;Manuela Gariboldi","doi":"10.1177/17246008211064915","DOIUrl":"https://doi.org/10.1177/17246008211064915","url":null,"abstract":"<p><strong>Introduction: </strong>Disease recurrence after surgery is a crucial predictor of poor prognosis in colorectal cancer, where disseminated disease at the time of intervention can also be observed in localized early-stage cases. We evaluated the ability to predict disease recurrence of miRNAs from two signatures that we have found linked to the presence of colorectal cancer (CL signature) or adenoma (HgA signature) in higher-risk subjects.</p><p><strong>Methods: </strong>miRNAs from the signatures were studied longitudinally by quantitative real-time polymerase chain reaction in plasma from 24 patients with resectable colorectal cancer collected at the time of surgery and during scheduled follow-up across 36 months. Patients either showed relapse within 36 months (alive with disease (AWD)), or remained disease-free (no evidence of disease (NED)) for the same period.</p><p><strong>Results: </strong>Although the signatures did not predict recurrence, expression of the miRNAs from the CL signature decreased 1 year after surgery, and one miRNA of the signature, miR-378a-3p, almost reached significance in the NED subgroup (Wilcoxon signed-rank test: <i>p</i>-value = 0.078). Also, miR-335-5p from the HgA signature was higher in AWD patients before surgery (Kruskal-Wallis test: <i>p</i>-value = 0.019).</p><p><strong>Conclusions: </strong>These data, although from a small cohort of patients, support the possible use of miRNAs as non-invasive biomarkers in liquid biopsy-based tests to identify patients at risk of relapse and to monitor them during follow-up.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"102-109"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39856371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer.","authors":"Linyan Zhang,&nbsp;Simeng Qin,&nbsp;Liuyi Lu,&nbsp;Li Huang,&nbsp;Shan Li","doi":"10.1177/17246008211072875","DOIUrl":"https://doi.org/10.1177/17246008211072875","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the diagnostic value of prealbumin-to-fibrinogen ratio (PFR) and albumin-to-fibrinogen ratio (AFR) alone or in combination in <i>Helicobacter pylori</i>-negative gastric cancer (Hp-NGC) patients.</p><p><strong>Methods: </strong>This study included 171 healthy controls, 180 Hp-NGC patients, and 215 <i>Helicobacter pylori</i>-negative chronic gastritis (HpN) patients. We compared the differences of various indicators and pathological characteristics between groups with Mann-Whitney U test and Chi-square test. The diagnostic value of PFR and AFR alone or in combination for Hp-NGC patients was assessed by the receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>PFR and AFR were related to the progression and clinicopathological characteristics of Hp-NGC. As the disease progressed, PFR and AFR values gradually decreased and were negatively related to the tumor size and depth of invasion. In addition, the area under the curves (AUCs) that resulted from combining PFR and AFR to distinguish Hp-NGC patients from healthy controls and HpN patients were 0.908 and 0.654, respectively. When combined with PFR and AFR in the differential diagnosis of tumors with a maximum diameter ≥ 5 cm and the T3 + T4 stage, the AUCs were 0.949 and 0.922; the sensitivity was 86.32% and 80.74%; and the specificity was 94.74% and 92.98%, respectively.</p><p><strong>Conclusions: </strong>PFR and AFR may be used as diagnostic biomarkers for Hp-NGC. The combination of PFR and AFR was more valuable than each indicator alone in the diagnosis of Hp-NGC.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"37 1","pages":"66-73"},"PeriodicalIF":2.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39923640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients.","authors":"Xintong Zhang,&nbsp;Shang Ma,&nbsp;Yan Chen,&nbsp;Yanjun Yin,&nbsp;Wanqiu Bai,&nbsp;Jinjing Tan,&nbsp;Guangli Shi","doi":"10.1177/17246008211052571","DOIUrl":"https://doi.org/10.1177/17246008211052571","url":null,"abstract":"<p><strong>Background: </strong>The serum isocitrate dehydrogenase 1(IDH1) level is significantly elevated in patients with non-small cell lung cancer (NSCLC) and has important clinical value as a marker for early diagnosis. This study examined the dynamic changes of serum IDH1 levels of patients with NSCLC undergoing surgery or medical treatment, to evaluate its potential prognostic value.</p><p><strong>Methods: </strong>The study cohort included 83 NSCLC patients who underwent surgery, 37 NSCLC patients who underwent medical treatment, 50 healthy controls, and 52 disease controls. Serum levels of IDH1 were assayed by enzyme-linked immunoassay. Tumor biomarkers including carcinoembryonic antigen, squamous cell carcinoma, neuron-specific enolase, CYFRA21-1, and pro-gastrin-releasing peptide-which are currently used in clinical practice-were measured by automatic immunoanalyzers.</p><p><strong>Results: </strong>Serum IDH1 was significantly higher in patients with NSCLC compared with healthy people or patients with benign lung diseases (<i>p</i> < 0.001). The area under the receiver operating characteristic curve for diagnosis and differential diagnosis were 0.897 and 0.879, respectively, which were superior to the five tumor markers. Serum IDH1 levels decreased in most patients after surgery, with the most dramatic changes in patients with stage I tumors compared with stage II and III. Analyses of changes in the serum IDH1 level of patients after receiving chemotherapy or targeted therapy revealed that for patients with progressive disease, serum IDH1 increased significantly after treatment; for patients with partial response or stable disease, it decreased steadily.</p><p><strong>Conclusion: </strong>IDH1 has potential prognostic value and may be used as a marker for the monitoring of treatment efficacy.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 4","pages":"27-35"},"PeriodicalIF":2.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39717885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}